Comparison of effectiveness of biosimilar filgrastim (Nivestim (TM)), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study

摘要

Biosimilars are supported by limited clinical data at the time of approval. Recently, Nivestim (TM), a biosimilar of reference of filgrastim, was approved for prevention of chemotherapy-related febrile neutropenia (FN). To add clinical experience to this new biosimilar, we performed a study to compare the effectiveness of Nivestim (TM) with reference filgrastim and pegfilgrastim in FN prevention in patients receiving high-risk FN chemotherapy.